Voyager Therapeutics Stock Price

-0.035 (-1.16%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Voyager Therapeutics Inc VYGR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.035 -1.16% 2.975 14:23:22
Open Price Low Price High Price Close Price Prev Close
3.00 2.97 3.0829 3.01
Bid Price Ask Price Spread News
2.97 2.98 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
947 57,585 $ 3.00 $ 172,502 - 2.82 - 12.65
Last Trade Time Type Quantity Stock Price Currency
14:29:24 2 $ 2.97 USD


Draw Mode:

Voyager Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 112.86M 37.94M 26.27M $ 171.13M $ 22.91M 0.96 6.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 397.00k 5.00%

more financials information »

Voyager Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VYGR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.273.352.953.04177,864-0.295-9.02%
1 Month3.153.632.953.23182,352-0.175-5.56%
3 Months4.124.222.823.38265,714-1.15-27.79%
6 Months5.615.972.824.34451,209-2.64-46.97%
1 Year11.6012.652.826.00424,854-8.63-74.35%
3 Years18.3628.792.8211.92394,885-15.39-83.8%
5 Years13.9031.912.8213.82351,788-10.93-78.6%

Voyager Therapeutics Description

Voyager Therapeutics Inc is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Your Recent History
Voyager Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.